You are here

Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it has entered into a lease agreement to develop a 118,000 square foot cell therapy manufacturing facility in Newark, California.
Wednesday, February 20, 2019 - 08:00